Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

Objectives

Fig. 04 -

Burden of Asthma

Fig. 05 -

Inpatient Exacerbation Burden

Fig. 06 -

Asthma Pathophysiology

Fig. 07 -

Inflammation in Asthma

Fig. 08 -

Asthma Goals

Fig. 09 -

Severe Asthma Definition

Fig. 10 -

Uncontrolled Asthma Definition

Fig. 11 -

Patient Evaluation

Fig. 12 -

Testing Available

Fig. 13 -

Asthma Mimickers

Fig. 14 -

Comorbid Conditions

Fig. 15 -

Stepwise Approach

Fig. 16 -

Asthma Control

Fig. 17 -

Guidelines Continued

Fig. 18 -

Phenotyping/Endotyping

Fig. 19 -

Asthma Phenotype/Endotype

Fig. 20 -

Phenotypes of Asthma

Fig. 21 -

Omalizumab

Fig. 22 -

Omalizumab and Placebo

Fig. 23 -

Global Evaluation

Fig. 24 -

QoL Scores

Fig. 25 -

Omalizumab Continued

Fig. 26 -

Mepolizumab

Fig. 27 -

Ortega Trial

Fig. 28 -

OCS Dependent

Fig. 29 -

Mepolizumab Trials

Fig. 30 -

Reslizumab

Fig. 31 -

Improvements

Fig. 32 -

Reslizumab Trials

Fig. 33 -

Benralizumab

Fig. 34 -

Calima and Sirocco

Fig. 35 -

Change from Baseline

Fig. 36 -

Benralizumab Trials

Fig. 37 -

Dupilumab

Fig. 38 -

Dupilumab Results

Fig. 39 -

Percentage Reduction

Fig. 40 -

Tiotroprium

Fig. 41 -

Change in Trial

Fig. 42 -

Severe Exacerbation

Fig. 43 -

Bronchial Thermoplasty

Fig. 44 -

Theoretical Basis

Fig. 45 -

Untreated vs Treated

Fig. 46 -

Major Human Studies

Fig. 47 -

Severe Exacerbation Reduction

Fig. 48 -

Symptom Free Days

Fig. 49 -

Improved QoL

Fig. 50 -

Randomized Sham Trial

Fig. 51 -

Precedure 1, 2, 3

Fig. 52 -

4 Activations

Fig. 53 -

Conclusion